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Open access under CC BY license.P.berghei ANKA infection in CBA or CB57BL/6 mice is
used widely as a murine ‘model’ of human cerebral
malaria (HCM), despite markedly different histopatholo-
gical features. The pathology of the murine model is
characterised by marked inflammation with little or no
intracerebral sequestration of parasitised erythrocytes,
whereas HCM is associated with intense intracerebral
sequestration, often with little inflammatory response.
There are now more than ten times as many studies each
year of the murine model than on HCM. Of 48 adjunctive
interventions evaluated in the murine model, 44 (92%)
were successful, compared with only 1 (6%) of 17 eval-
uated in HCM during the same period. The value of the
mouse model in identifying pathological processes or
therapeutic interventions in human cerebral malaria is
questionable.
Cerebral malaria – in mice and men
Obtundation and stupor are usual in the agonal phase of
any acute lethal infection, and can occur transiently in
many febrile infections including malaria, but the syn-
drome of human cerebral malaria (HCM) is distinct. Most
(80–85%) patients survive, and most have no evident
residual ‘structural’ neurological deficits [1]. HCM is a
major cause of death in tropical countries, and yet there
have been remarkably few pathological studies of severe
falciparum malaria, particularly from Africa, where the
majority of deaths occur [2]. The only interventions that
have reduced the mortality of severe falciparum malaria
are antimalarial drugs and haemofiltration for malaria-
associated acute renal failure [3,4]. Many adjunctive treat-
ments have been tried that were based on the prevailing
pathophysiological hypotheses of the time. None was
clearly beneficial, although most clinical studies were
insufficiently powered to detect anything but dramatic
reductions in mortality. Several interventions (heparin,
dexamethasone, phenobarbitone, anti-TNF antibody)
appeared harmful [5–7]. In recent years, clinical trial net-
works have been established, and large clinical trials have
been conducted in adults and children with severe falci-
parummalaria, powered to show reductions in mortality of
one-third or less [3,8–10]. Large trials take time and are
costly. Probably only one or two can be conducted in the
world at any time, so the choice of the intervention and theCorresponding author: White, N.J. (nickw@tropmedres.ac)
1471-4922 2009 Elsevier Ltd. All rights reserved. doi:10.1016/j.pt.2009.10.007design of the trial are crucial. These networks could soon be
used to evaluate adjunctive treatments or other aspects of
supportive care – but which ones?
Over the past 20 years there has been a remarkable
increase in the number of laboratory-based studies in
temperate countries on a murine ‘model’ of cerebral
malaria involving Plasmodium berghei (ANKA strain) in-
fection of C57BL/6 or CBA mice. Instead of dying slowly
from anaemia, mice with this particular infection die more
rapidly (in the second week of infection) from a cerebral
syndrome associatedwith seizures. This is a specificmodel,
requiring a specific combination of parasite and host,
because infections with the majority of P. berghei strains,
and in most of the other strains of mice tested, do not cause
a lethal encephalopathy. So what do the results of these
numerous murine studies tell us about the infection in
humans? (There are now over ten times more murine
studies per year than there are studies on HCM)
(Figure 1). And how can they be used to guide our thera-
peutic assessments? These are legitimate questions in that
most grant applications to support research on murine
cerebral malaria start with, andmost papers on the ‘model’
conclude with, a statement that the results of the studies
are of relevance to either the pathogenesis or the treatment
of human cerebral malaria.
The pathology of human cerebral malaria
The seminal pathology studies of Marchiafava and his
colleagues at the end of the 19th century [11] showed that
red blood cells (RBCs) containing mature stages of Plasmo-
dium falciparum malaria parasites are sequestered in the
capillaries andpost-capillary venules of the brain (Figure2),
and reduce the vascular lumen to create a mechanical
obstruction to RBC transit. This was later shown to result
from specific adherence of parasitised RBCs to the vascular
endothelium (cytoadherence).ParasitisedRBCsalsoadhere
to uninfected RBCs (rosetting) and to other infected RBCs
(auto-agglutination). In severe malaria (but not in sepsis)
the entire RBC population becomes rigid, further compro-
mising flow through capillaries that have a mid-point
diameter smaller than the erythrocyte itself [12]. Although
there are similarities between the clinical presentations of
severe malaria and bacterial septicaemia, and the two
commonly co-exist, the fundamental microvascular
pathology is different [13]. Disease severity in severe falci-
parummalaria is proportional to the estimated sequesteredAvailable online 22 November 2009 11
Figure 1. Annual numbers of publications describing studies on human cerebral
malaria (HCM) (blue) and murine models of cerebral malaria (orange) since 1980
listed on the National Library of Medicine (NLM) PubMed. The medical subject
headings (MeSH) search terms were: human/cerebral malaria; subheadings,
therapy, drug therapy, diet therapy/physiopathology, pathology; limits,
concerning therapy: clinical trials. MeSH: mouse/cerebral malaria; subheadings,
therapy, drug therapy, diet therapy/physiopathology, pathology; limits, none. After
compilation, the lists were checked manually.
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reflected in the reproducible observation that hyperlacta-
taemia, with an increased lactate:pyruvate ratio, and acido-
sis are among the strongest prognostic indicators in adults
and children with severe malaria [15–17]. The degree of
microvascular obstruction and reduction in blood flow
assessed directly in vivo correlateswith the degree of hyper-
lactataemia [13]. Coma is associated quantitatively with
cerebral sequestration [18]. In otherwords, patientswhodie
fromHCMhavemore parasitised erythrocyte sequestration
in the cerebralmicrovasculature than do thosewho die from
dysfunction of other vital organs. In some fatal cases,
cerebral sequestration is not evident. These patients often
had received antimalarial treatment for several days and
cleared most intracerebral parasites (although residual
adherent erythrocyte membranes and pigment commonly
remain, testifying to earlier and more intense intracerebral
sequestration). There are other causes of coma, such as
status epilepticus [19] or a post-ictal state; indeed, the
diagnosis of cerebral malaria could be incorrect, and coma
could have a different causation [2]. Severe malaria is
certainly overdiagnosed in endemic areas where the
majority of the population is parasitised [20]. Our interpret-
ation of the combined pathological evidence is that intracer-
ebral sequestrationof parasitised erythrocytes causes coma,
and is therefore the primary cause of HCM, although the
relative contributions of endothelial activation and dysfunc-
tion, reversible axonal dysfunction, and other local and
systemic factors are not known [21–23]. There has been
considerable debate as to the extent and importance of
inflammatory changes in the brain in HCM [2,24–26]. Pro-
tagonists point to systemic pro-inflammatory cytokine
responses (as inmost febrile infections), evidence of platelet
and some leukocyte accumulation in the cerebral microvas-
culature, particularly in children [27], and a moderate
increase in blood–brain barrier permeability. Others point
to the complete absence of inflammatory changes in many
patients dying in the acute phase of cerebral malaria with a
cerebral microvasculature engorged by cytoadherent para-
sitised erythrocytes [18,24,28–30].12Animal ‘models’ of cerebral malaria
Ideally, prospective interventions should be tested in an
animal model before being evaluated in the corresponding
human disease. Unfortunately there is no good animal
model that reproduces both the clinical and pathophysio-
logical features of cerebral malaria in humans. Aotus and
Saimirimonkeys and chimpanzees can be infected with P.
falciparum, and bothP. coatneyi and P. fragile infections in
macaque monkeys are associated with sequestration of
parasitised RBCs in the microvasculature, although
cerebral sequestration is not prominent [31–33]. A rodent
model of cerebral malaria was first proposed 35 years ago
[34]. In recent years, infections with P. berghei ANKA
strain in C57BL/6 or CBA mice have been studied almost
exclusively. The murine malaria encephalopathy is very
different from human cerebral malaria. It has an unequi-
vocally immunological basis in which pro-inflammatory
cytokines play a central role. P. berghei ANKA-infected
murine erythrocytes do sequester to some extent in the
microvasculature of mice, via adhesion to CD36 (as does P.
falciparum), but they sequester mainly in the lungs and in
adipose tissue rather than in the brain [35]. The funda-
mental and obvious pathological difference with HCM is
that there is marked accumulation of leukocytes and pla-
telets in the venules and capillaries of the brain in the
murine model instead of parasitised RBC sequestration
(Figure 2). Thus, whereas there is often little or no cyto-
pathological evidence of inflammation in fatal HCM, this is
the hallmark of the murine model. In CD36/ mice
infected with P.berghei ANKA there is no microvascular
sequestration of parasitised erythrocytes but the cerebral
syndrome still occurs. Curiously, rather than challenging
the relevance of the murine model, this finding was taken
to support a dissociation between cerebral sequestration
and the causation of human cerebral malaria [35]!
Despite these fundamental differences, the murine and
human syndromes are discussed together as if they shared
a similar pathology. There is an increasing trend for
authors to drop the adjective ‘murine’ from their descrip-
tion of experimental cerebral malaria. A large and remark-
ably diverse array of interventions has been effective in the
mouse model (Table S1 in the supplementary material
online). Somemake strange bedfellows (anti-TNF antibody
and recombinant TNF, oxidants and anti-oxidants,
starvation and obesity). Interventions based on an incor-
rect understanding of pathology can be harmful, as shown
previously. Given the considerable differences between the
murine and human cerebral syndromes, can we justify
evaluating any of these interventions in man, and – if so
– which one?
Responses to interventions
Since the first adjunctive intervention (anti-TNF antibody)
in the murine model was evaluated 22 years ago, 48
different potential therapeutic interventions have been
evaluated in 45 studies (Table S1 in the supplementary
material online). All but four (92%) have either prevented
or ameliorated the cerebral syndrome. Of these four excep-
tions, COX2 inhibition by celecoxib made it worse, whereas
indomethacin, simvastatin and anti-apoptotic strategies
had no effect. The results of the interventions have usually
Figure 2. A comparison of the histopathological hallmarks of human cerebral malaria (HCM) and the Plasmodium berghei ANKA murine model. (a) Parasitised erythrocyte
sequestration in small and large vessels from a patient who died during the acute phase of cerebral malaria. (b) A large vessel containing numerous mononuclear
leukocytes but no sequestered parasitised erythrocytes from a mouse at the terminal stage of the disease. Sections are from cerebral cortex counterstained with
haematoxylin. Scale bar, 50 mm.
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syndrome by more than 50%, and often by 100% [36]. By
comparison, in the same period, 11 adjunctive interventions
were evaluated in 17 clinical trials in severe human HCM.
Only one (with human albumin) was claimed to provide a
mortality advantage, and two other interventions (desfer-
rioxamine and pentoxyfilline) claimed acceleration in the
recovery from coma.However, for both desferrioxamine and
pentoxyfilline, other trials did not confirm the benefit. None
of the adjunctive treatments evaluated in HCM before the
murine cerebral malaria era was clearly beneficial either.
Dexamethasone, pentoxyfilline, anti-TNF antibody and
aspirinwere evaluated in bothmice andmen,with dramatic
benefits in encephalopathic mice, but not in humans with
cerebral malaria. Murine AIDS also protects mice from
‘cerebral malaria’, but HIV infection predisposes to, rather
than ameliorates, severe malaria in semi-immune subjects.
In summary, whereas nearly all evaluated interventions
have been dramatically effective in themurinemodel, there
is no convincing evidence of benefit for any adjunctive
intervention in human cerebral malaria, although the jury
remains out (awaiting the results of largemulticentre trials)
on the role of albumin.
The timing of adjunctive treatment
The relevance of murine ‘cerebral malaria’ intervention
results to the treatment of HCM is further challenged by
the timing of intervention. In severe falciparum malaria,
sequestration of parasitised erythrocytes contributes to
the development of coma and subsequent death. There is
now good evidence that antimalarial treatment with arte-
misinin derivatives, that prevent sequestration by killing
circulating ring forms of the parasite, significantly reduces
mortality [3]. Studies using murine models have typically
examined survival benefits following administration of the
adjunctive treatment to animals before the development of
neurological signs. Once these develop, adjuvant treat-
ments are much less effective. Adjunctive treatments in
murine ‘cerebral malaria’ are not evaluated with, or com-
pared to, effective antimalarial drugs, that would be the
context of use in treating human falciparum malaria.Reconciling clinical and laboratory research on severe
malaria
In recent years there has been very little clinicopatholo-
gical research on HCM, whereas there has been a dramatic
increase in laboratory research on the murine ‘model’
(Figure 1). This neuropathological process in CBA or
C57BL/6 mice infected with the P.berghei ANKA strain
has been called ‘cerebral malaria’, a term adopted from
clinical medicine because mice with this malaria develop
neurological signs. It shares the name, but very little else,
with the human disease. The histopathology and the
responsivity to interventions are dramatically different.
It is clear that the murine disease is primarily an immu-
nopathological process, whereas endothelial activation and
dysfunction in HCM are associated with the sequestration
of parasitised RBC, and the primary role of immune mech-
anisms is questionable. Interestingly, pulmonary pathol-
ogy in the murine model is clearly associated with
parasitised RBC sequestration [35,37], and may have a
stronger case than the encephalopathy to be a model of
human disease. Why some P. falciparum parasites seques-
ter preferentially in the human cerebral microvasculature
is not known, but this question is unlikely to be answered
by an animal model in which white cells, rather than
parasitised RBC, accumulate in the brain.
The timing and context of interventions evaluated in the
murine model are unrealistic. In the mouse, the interven-
tions are usually assessed before or at the onset of the
cerebral syndrome in the absence of antimalarial drugs.
In clinical practice, patients are treated immediately with
antimalarial drugs. Therefore they seldom present to
medical attention ‘before cerebralmalaria’ because effective
antimalarial treatmentwithartemisininderivatives largely
prevents it. Most patients who develop cerebral malaria are
already unconscious when they present to medical atten-
tion, and they are treated immediately with a parenteral
antimalarial.Noadjunctive treatment is of provenbenefit in
HCM, whereas nearly everything seems to be dramatically
effective in the murine model (including interventions that
have been ineffective inHCM). Indeed, it is remarkable just
how many completely different interventions prevent the13
Opinion Trends in Parasitology Vol.26 No.1murine neurological syndrome. Of course, it may be that
other ineffective interventions were not reported. It must
also be conceded that the statistical power of themajority of
intervention trials in HCM has been limited. Only four
clinical trials recruited more than 100 patients per treat-
ment arm. Therefore, although dramatic benefits have been
excluded, small (but clinically important) benefits cannot be
excluded by these human clinical studies.
The investigation of murine cerebral malaria has now
developed into an independent and self-sustaining epis-
teme. Murine malaria studies usually build on established
laboratory research programmes, use genetically homo-
geneous parasites in genetically homogeneous hosts, pro-
vide standardised high quality histopathology on all
subjects, give ‘positive’ results, and provide immunological
and pathological supporting material, and these appeal to
a substantial laboratory-based immunology caucus. The
study reports seldom question the relevance of themodel to
clinical medicine or to the human disease. Despite the
marked differences in pathology, and the unrealistic
clinical setting evaluated in the murine model, reports
of successful interventions in the mouse usually conclude
that the interventionmay benefit human cerebral malaria.
This extrapolation, that may carry considerable weight in
the decision to publish, seems unjustified. To illustrate the
disconnect, of the eight potential adjunctive treatments for
severe malaria now being evaluated in humans (L-argi-
nine, N-acetyl cysteine, albumin, mannitol, erythropoetin,
levamisole, activated charcoal, early enteral feeding) only
two (erythropoietin and activated charcoal) derive from
studies in the murine model (http://www.controlled-trials.-
com/mrct/search.html).
Animal models can provide very valuable biological
information. Our concerns are with this particular model,
the use of one term (i.e. ‘cerebral malaria’) to describe two
very different clinicopathological processes, and inference
from observations in this model to potential interventions
in HCM [38,39]. Given the considerable differences be-
tween murine ‘cerebral malaria’ and HCM, in pathology
and in susceptibility to adjunctive interventions, it is
legitimate to question the relevance, and thus the utility
of this mouse model.
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